Lucid Diagnostics Inc.
LUCD · NASDAQ
| Reporting period ended | 9/30/2025 Q3 2025 | 6/30/2025 Q2 2025 | 3/31/2025 Q1 2025 | 12/31/2024 Q4 2024 |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.08 | -0.01 | 0.05 |
| FCF Yield | -10.00% | -9.29% | -12.25% | -21.44% |
| EV / EBITDA | -0.01 | -26.19 | -4.22 | -4.08 |
| Quality | ||||
| ROIC | -23,438.31% | -32.14% | -41.77% | -46.44% |
| Gross Margin | -40.13% | -53.48% | -87.32% | -79.20% |
| Cash Conversion Ratio | 1.05 | 2.38 | 0.46 | 0.86 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -3.28% | 15.80% | -23.97% | 3.75% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 0.85 | -0.38 | 0.10 |
| Interest Coverage | -5,879.50 | -1,897.33 | -1,387.44 | -1,767.86 |
| Efficiency | ||||
| Inventory Turnover | 1,982.48 | 1.82 | 3.20 | 6.29 |
| Cash Conversion Cycle | 0.05 | 36.33 | -13.39 | -7.31 |